Skip to main content
Premium Trial:

Request an Annual Quote

With Only Grant Revenue Trickling In, Helicos' R&D Costs Deepen Q3 Loss

NEW YORK (GenomeWeb News) — In its second quarterly earnings report since its initial public offering in May, Helicos today said it gained minimal revenue from grants while R&D spending rose 73 percent and its net loss grew by 68 percent compared to the prior-year period.
Total receipts for its third quarter ended Sept. 30 were $230,000 while the company claimed no revenue for the third quarter of 2006.
The company said all of its revenue for the quarter, and for the year to date, came from grants from the National Institutes of Health.
Helicos’ R&D spending for the third quarter rose to $7.2 million from $4.2 million year over year, and its general and administrative costs nearly doubled to $3.6 million from $1.9 million.
The firm's net loss swelled to $10 million from $5.9 million in the comparable period of 2006.
As of Sept. 30, Helicos had $54.9 million in combined cash and cash equivalents.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.